Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faldaprevir and TD-6450 in Genotype 1b HCV
NCT02716428Phase 2Completed
- Sponsor
- Trek Therapeutics
- Start
- May 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of faldaprevir, TD-6450 in hepatitis C (HCV), sponsored by Trek Therapeutics. Started May 2016; status: completed.
02
Drugs
faldaprevirTD-6450
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02716428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716428.